Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy

José Pablo Leone, Adrian V Lee, Adam M Brufsky, José Pablo Leone, Adrian V Lee, Adam M Brufsky

Abstract

Brain metastasis (BM) in patients with breast cancer is a catastrophic event that results in poor prognosis. Identification of prognostic factors associated with breast cancer brain metastases (BCBM) could help to identify patients at risk. The aim of this study was to assess clinical characteristics, prognostic factors, and survival of patients with BCBM who had craniotomy and resection in a series of patients treated with modern multimodality therapy. We analyzed 42 patients with BCBM who underwent resection. Patients were diagnosed with breast cancer between April 1994 and May 2010. Cox proportional hazards regression was selected to describe factors associated with time to BM, survival from the date of first recurrence, and overall survival (OS). Median age was 51 years (range 24-74). Median follow-up was 4.2 years (range 0.6-18.5). The proportion of the biological subtypes of breast cancer was ER+/HER2- 25%, ER+/HER2+ 15%, ER-/HER2+ 30%, and ER-/HER2- 30%. Median OS from the date of primary diagnosis was 5.74 years. Median survival after diagnosis of BM was 1.33 years. In multivariate Cox regression analyses, stage was the only factor associated with shorter time to the development of BM (P = 0.033), whereas age was the only factor associated with survival from the date of recurrence (P = 0.027) and with OS (P = 0.037). Stage at primary diagnosis correlated with shorter time to the development of BM, while age at diagnosis was associated with shorter survival in BCBM. None of the other clinical factors had influence on survival.

Keywords: Brain metastasis; breast cancer; craniotomy; prognostic factors; survival.

© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Kaplan–Meier curve for survival from date of brain metastasis.
Figure 2
Figure 2
Kaplan–Meier curve for overall survival.

References

    1. Lin NU, Bellon JR. Winer EP. CNS metastases in breast cancer. J. Clin. Oncol. 2004;22:3608–3617.
    1. Arslan C, Dizdar O. Altundag K. Systemic treatment in breast-cancer patients with brain metastasis. Expert Opin. Pharmacother. 2010;11:1089–1100.
    1. Tham YL, Sexton K, Kramer R, Hilsenbeck S. Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006;107:696–704.
    1. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG) Ann. Oncol. 2006;17:935–944.
    1. Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res. 2008;10:R20.
    1. Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J. Clin. Oncol. 2006;24:5658–5663.
    1. Brogi E, Murphy CG, Johnson ML, Conlin AK, Hsu M, Patil S, et al. Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays. Ann. Oncol. 2011;22:2597–2603.
    1. Duchnowska R, Dziadziuszko R, Czartoryska-Arlukowicz B, Radecka B, Szostakiewicz B, Sosinska-Mielcarek K, et al. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res. Treat. 2009;117:297–303.
    1. Lee SS, Ahn JH, Kim MK, Sym SJ, Gong G, Ahn SD, et al. Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res. Treat. 2008;111:523–530.
    1. Ogawa K, Yoshii Y, Nishimaki T, Tamaki N, Miyaguni T, Tsuchida Y, et al. Treatment and prognosis of brain metastases from breast cancer. J. Neurooncol. 2008;86:231–238.
    1. Gil-Gil MJ, Martinez-Garcia M, Sierra A, Conesa G, Del Barco S, Gonzalez-Jimenez S, et al. Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline. Clin. Transl. Oncol. 2014;16:436–446.
    1. Niwinska A, Pogoda K, Murawska M. Niwinski P. Factors influencing survival in patients with breast cancer and single or solitary brain metastasis. Eur. J. Surg. Oncol. 2011;37:635–642.
    1. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL. Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
    1. Tarhan MO, Demir L, Somali I, Yigit S, Erten C, Alacacioglu A, et al. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival. Clin. Exp. Metastasis. 2013;30:201–213.
    1. Saip P, Cicin I, Eralp Y, Kucucuk S, Tuzlali S, Karagol H, et al. Factors affecting the prognosis of breast cancer patients with brain metastases. Breast. 2008;17:451–458.
    1. Boogerd W. Central nervous system metastasis in breast cancer. Radiother. Oncol. 1996;40:5–22.
    1. Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br. J. Cancer. 2004;91:639–643.
    1. Minisini AM, Moroso S, Gerratana L, Giangreco M, Iacono D, Poletto E, et al. Risk factors and survival outcomes in patients with brain metastases from breast cancer. Clin. Exp. Metastasis. 2013;30:951–956.
    1. Musolino A, Ciccolallo L, Panebianco M, Fontana E, Zanoni D, Bozzetti C, et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer. 2011;117:1837–1846.
    1. Wronski M, Arbit E. McCormick B. Surgical treatment of 70 patients with brain metastases from breast carcinoma. Cancer. 1997;80:1746–1754.
    1. Bai B, Yuan ZY, Liu DG, Teng XY. Wang SS. Clinical features and survival analysis of different subtypes of patients with breast cancer brain metastases. Chin. J. Cancer. 2010;29:413–419.
    1. Hung MH, Liu CY, Shiau CY, Hsu CY, Tsai YF, Wang YL, et al. Effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients. PLoS ONE. 2014;9:e89389.
    1. Park BB, Uhm JE, Cho EY, Choi YL, Ji SH, Nam do H, et al. Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes? Cancer Chemother. Pharmacol. 2009;63:627–633.
    1. Harputluoglu H, Dizdar O, Aksoy S, Kilickap S, Dede DS, Ozisik Y, et al. Characteristics of breast cancer patients with central nervous system metastases: a single-center experience. J. Natl. Med. Assoc. 2008;100:521–526.
    1. Arslan UY, Oksuzoglu B, Aksoy S, Harputluoglu H, Turker I, Ozisik Y, et al. Breast cancer subtypes and outcomes of central nervous system metastases. Breast. 2011;20:562–567.
    1. Wiksyk B, Nguyen DH, Alexander C. Truong PT. Population-based analysis of treatment and survival in women presenting with brain metastasis at initial breast cancer diagnosis. Am. J. Clin. Oncol. 2014 , and 2014 Feb 26. [Epub ahead of print]
    1. DiStefano A, Yon YY, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer. 1979;44:1913–1918.
    1. Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann. Oncol. 2009;20:621–627.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅